All studies
Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional
A Phase 2 double blind, randomized, placebo controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participants with multiple sclerosis, followed by an open-label long-term extension period
At a glance
Status
Ongoing, recruiting
Phase
Therapeutic exploratory (Phase II)
Sponsor
Sanofi-Aventis Recherche & Developpement
Enrolment target
157
Start
24 Apr 2024
What is this study about?
Part A: Week 48 sNfL levels relative to baseline, Part B: Week 96 sNfL levels relative to baseline
Who may be eligible?
Age 18 Years to any · Sex: All
Locations (7)
- —Spain
- —Belgium
- —Germany
- —Italy
- —Bulgaria
- —Poland
- —France
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.